Market closed
UroGen Pharma/$URGN
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About UroGen Pharma
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
Ticker
$URGN
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
217
Website
UroGen Pharma Metrics
BasicAdvanced
$452M
Market cap
-
P/E ratio
-$3.08
EPS
1.13
Beta
-
Dividend rate
Price and volume
Market cap
$452M
Beta
1.13
52-week high
$20.70
52-week low
$10.54
Average daily volume
382K
Financial strength
Current ratio
9
Quick ratio
8.307
Long term debt to equity
477.84
Total debt to equity
481.074
Interest coverage (TTM)
-6.85%
Management effectiveness
Return on assets (TTM)
-21.12%
Return on equity (TTM)
1,400.39%
Valuation
Price to revenue (TTM)
4.484
Price to book
17.71
Price to tangible book (TTM)
17.71
Price to free cash flow (TTM)
-4.158
Growth
Revenue change (TTM)
15.64%
Earnings per share change (TTM)
-25.05%
3-year revenue growth (CAGR)
30.91%
3-year earnings per share growth (CAGR)
-15.26%
What the Analysts think about UroGen Pharma
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for UroGen Pharma stock.
UroGen Pharma Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
UroGen Pharma Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
UroGen Pharma News
AllArticlesVideos
Long-Term Follow-up Study to the OLYMPUS Trial Presented at SUO 2024 Reports Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO®
Business Wire·2 weeks ago
UGN-102 Showed Promising Long-Term Results in the Phase 3 ENVISION Trial, Potentially Paving the Way for First FDA-Approved Treatment for LG-IR-NMIBC
Business Wire·2 weeks ago
UroGen Pharma: Choice Based On Near Term High Value PDUFA
Seeking Alpha·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for UroGen Pharma stock?
UroGen Pharma (URGN) has a market cap of $452M as of December 21, 2024.
What is the P/E ratio for UroGen Pharma stock?
The price to earnings (P/E) ratio for UroGen Pharma (URGN) stock is 0 as of December 21, 2024.
Does UroGen Pharma stock pay dividends?
No, UroGen Pharma (URGN) stock does not pay dividends to its shareholders as of December 21, 2024.
When is the next UroGen Pharma dividend payment date?
UroGen Pharma (URGN) stock does not pay dividends to its shareholders.
What is the beta indicator for UroGen Pharma?
UroGen Pharma (URGN) has a beta rating of 1.13. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.